Skip to main content

Table 3 Treatment-related adverse events

From: Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma

Adverse events

All grades

(n, %)

Grade3-4

(n, %)

Hypertension

60

(58.8)

20

(19.6)

Hand-foot syndrome

49

(48.0)

7

(6.9)

Stomatitis

36

(35.3)

6

(5.9)

Dysgeusia

17

(16.7)

-

-

Oedema

14

(13.7)

0

(0)

Nausea / Vomiting

24

(23.5)

0

(0)

Hemorrhage

26

(25.5)

0

(0)

Constipation

16

(15.7)

0

(0)

Diarrhea

29

(28.4)

3

(2.9)

Fatigue

46

(45.1)

7

(6.9)

Hypothyroidism

26

(25.5)

5

(4.9)

Leukopenia

55

(53.9)

10

(9.8)

Thrombocytopenia

79

(77.5)

17

(16.7)

Anemia

70

(68.6)

5

(4.9)

Elevation of AST

63

(61.8)

8

(7.8)

Elevation of serum creatinine

53

(52.0)

5

(4.9)

Elevation of ALP

51

(51.5)

1

(1.0)

  1. AST Aspartate aminotransferase, ALP Alkaline phosphatase